Dr. Younes Discusses FDA Approval of Nivolumab in Hodgkin Lymphoma

Anas Younes, MD
Published: Monday, Jul 25, 2016


Anas Younes, MD, chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma (cHL).

This approval will have a significant impact on the treatment landscape of cHL as brentuximab vedotin (Adcetris) was previously the only approved agent in this space, Younes explains. Brentuximab vedotin is associated with a 75% response rate and a 35% complete response rate in patients with cHL. This means the majority of patients achieve partial, short-lived remissions; therefore, nivolumab provides a second option for this population.

Ongoing combination trials are examining nivolumab plus brentuximab vedotin, both of which can be administered at full doses, Younes explains. Nivolumab will also be explored in combination with chemotherapy and other targeted agents, he says.

Anas Younes, MD, chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma (cHL).

This approval will have a significant impact on the treatment landscape of cHL as brentuximab vedotin (Adcetris) was previously the only approved agent in this space, Younes explains. Brentuximab vedotin is associated with a 75% response rate and a 35% complete response rate in patients with cHL. This means the majority of patients achieve partial, short-lived remissions; therefore, nivolumab provides a second option for this population.

Ongoing combination trials are examining nivolumab plus brentuximab vedotin, both of which can be administered at full doses, Younes explains. Nivolumab will also be explored in combination with chemotherapy and other targeted agents, he says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x